Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study.

Ikuko TanakaYoshiya TanakaSatoshi SoenHisaji Oshima

Published in: Journal of bone and mineral metabolism (2020)

The non-inferiority of once-weekly teriparatide versus once-weekly alendronate in BMD change at 72 weeks was not shown, but the increase in bone formation markers over time and the increase of BMD in GIOP patients treated with once-weekly teriparatide were confirmed.

Keyphrases

bone mineral density
postmenopausal women
high glucose
endothelial cells